Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: Just the tip of the iceberg?

Adrian M. Bisceglie, Anna S. Lok, Paul Martin, Norah Terrault, Robert P. Perrillo, Jay H. Hoofnagle – 21 November 2014 – Reactivation of hepatitis B in the context of immunosuppressive therapy may be severe and potentially fatal. The US Food and Drug Administration has recently drawn attention to the potentially fatal risk of hepatitis B reactivation in patients receiving the anti‐CD20 agents ofatumumab or rituximab.

The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B

Liang Peng, Qiang Zhao, Qibin Li, Miaoxin Li, Caixia Li, Tingting Xu, Xiangyi Jing, Xiang Zhu, Ye Wang, Fucheng Li, Ruihong Liu, Cheng Zhong, Qihao Pan, Binghui Zeng, Qijun Liao, Bin Hu, Zhao‐xia Hu, Yang‐su Huang, Pak Sham, Jinsong Liu, Shuhua Xu, Jun Wang, Zhi‐liang Gao, Yiming Wang – 21 November 2014 – In the past 50 years there have been considerable efforts to identify the cellular receptor of hepatitis B virus (HBV).

Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression

Romina Salpini, Luna Colagrossi, Maria Concetta Bellocchi, Matteo Surdo, Christina Becker, Claudia Alteri, Marianna Aragri, Alessandra Ricciardi, Daniele Armenia, Michela Pollicita, Fabiola Di Santo, Luca Carioti, Yoram Louzoun, Claudio Maria Mastroianni, Miriam Lichtner, Maurizio Paoloni, Mariarosaria Esposito, Chiara D'Amore, Aldo Marrone, Massimo Marignani, Cesare Sarrecchia, Loredana Sarmati, Massimo Andreoni, Mario Angelico, Jens Verheyen, Carlo‐Federico Perno, Valentina Svicher – 21 November 2014 – Hepatitis B virus (HBV) reactivation during immunosuppression can lead to severe acute

Cre‐ativity in the liver: Transgenic approaches to targeting hepatic nonparenchymal cells

Stephen N. Greenhalgh, Kylie P. Conroy, Neil C. Henderson – 21 November 2014 – Rapid evolution in transgenic (Tg) mouse technology now permits cell‐specific and temporal control of fluorescent cell‐labeling and gene inactivation. Here, we discuss the principal strategies that have been utilized to target, label, and manipulate hepatic nonparenchymal cells, with emphasis on the utility of constitutive and inducible Cre‐lox systems.

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: Just the tip of the iceberg?

Adrian M. Bisceglie, Anna S. Lok, Paul Martin, Norah Terrault, Robert P. Perrillo, Jay H. Hoofnagle – 21 November 2014 – Reactivation of hepatitis B in the context of immunosuppressive therapy may be severe and potentially fatal. The US Food and Drug Administration has recently drawn attention to the potentially fatal risk of hepatitis B reactivation in patients receiving the anti‐CD20 agents ofatumumab or rituximab.

Cardiac tamponade following liver transplantation after intrapericardial control of the suprahepatic vena cava

Junming Xu, Johnny C. Hong, Ronald W. Busuttil – 19 November 2014 – Transabdominal intrapericardial control of the suprahepatic inferior vena cava (SIVC) is a rather uncommon procedure occasionally required in conjunction with complicated liver transplantation (LT) and hepatobiliary surgery. Experience with this technique is limited. Here we report 6 cases of LT in which transabdominal intrapericardial control of the SIVC was necessary.

Subscribe to